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Abstract. 
Endothelin-1 (ET-1) is elevated in patients with atrial fibrillation (AF) and heart failure. We investigated 
effects of ET-1 on human atrial cellular electrophysiological measurements expected to influence the genesis 
and maintenance of AF. Action potential characteristics and L-type Ca
2+
 current (ICaL) were recorded by 
whole cell patch clamp, in atrial isolated myocytes obtained from patients in sinus rhythm. Isoproterenol 
(ISO) at 0.05 µM prolonged the action potential duration at 50% repolarisation (APD50: 54±10 vs 28±5 ms; 
P<0.05, n=15 cells, 10 patients), but neither late repolarisation nor cellular effective refractory period (ERP) 
were affected. ET-1 (10 nM) reversed the effect of ISO on APD50, and had no basal effect (in the absence of 
ISO) on repolarisation or ERP. During repetitive stimulation, ISO (0.05 µM) produced arrhythmic 
depolarisations (P<0.05). Each was abolished by ET-1 at 10 nM (P<0.05). ISO (0.05 µM) increased peak 
ICaL from -5.5±0.4 to -14.6±0.9 pA/pF (P<0.05; n=79 cells, 34 patients). ET-1 (10 nM) reversed this effect by 
98±10% (P<0.05), with no effect on basal ICaL. Chronic treatment of patients with a β-blocker did not 
significantly alter basal APD50 or ICaL, the increase in APD50 or ICaL by 0.05 µM ISO, nor the subsequent 
reversal of this effect on APD50 by 10 nM ET-1. The marked anti-adrenergic effects of ET-1 on human atrial 
cellular action potential plateau, arrhythmic depolarisations and ICaL, without affecting ERP and 
independently of β-blocker treatment, may be expected to contribute a potentially anti-arrhythmic influence 
in the atria of patients with AF and heart failure.  
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Introduction. 
 Endothelin-1 exerts a wide variety of cardiovascular effects [1-3]. The consequences of these on the 
cardiac rhythm are currently under investigation. They may be influenced by the concentration of ET-1, the 
species and cardiac chamber studied, the presence of adrenergic stimulation and the degree of any coronary 
vasoconstriction by ET-1 [1,3]. Endothelin-1 provoked arrhythmias in the ventricles, by prolonging action 
potentials and promoting afterdepolarisations, particularly in dogs in-vivo [4-6]. The effects of ET-1 on atrial 
arrhythmias, such as atrial fibrillation (AF), however, are less clear. Recent reports have highlighted 
potentially pro-arrhythmic effects on intracellular Ca
2+
 ((Ca
2+
)i) handling, via activation of inositol-1,4,5 
trisphosphate (IP3) receptors [7-10]. Endothelin-1 also produced arrhythmic contractions in human atria [11]. 
However, to our knowledge, the effects of ET-1 on human atrial electrophysiological activity likely to 
influence the genesis and/or maintenance of AF have not been studied. 
 Endothelin-1 has consistently been reported to exert a marked anti-adrenergic reduction in L-type Ca
2+
 
current (ICaL) in both the atria and ventricles [12-15]. This effect is invariably and substantially larger than 
any change by ET-1 in basal (non-adrenergically-stimulated) ICaL [12-15], including in human atria [13,14]. 
The ICaL is a major determinant of action potential morphology, including in human atrial cells [16]. This 
current also may play a role in the development of abnormal automaticity and afterdepolarisations, both early 
(EAD) and delayed (DAD) [17]. Plasma ET-1 elevation is independently associated with AF in patients with 
congestive heart failure (CHF) [18,19]. Since catecholamines also are elevated in CHF [20], it is conceivable 
that such anti-adrenergic reduction in atrial ICaL by ET-1 might attenuate AF genesis, by inhibiting abnormal 
automaticity, EADs or DADs. However, it might also promote re-entrant AF, by shortening the action 
potential and effective refractory period (ERP). The effects of ET-1 on either action potentials or these 
arrhythmogenic electrophysiological mechanisms have not been studied in human atrial cells. 
 Beta-adrenoceptor antagonists (β-blockers) are increasingly used to treat patients with AF and CHF. 
These drugs may oppose pro-arrhythmic influences of elevated sympathetic drive. They may also potentiate 
atrial arrhythmic contractions induced by ET-1 and catecholamines [11,21]. We have demonstrated that long 
term treatment of patients with a β-blocker was associated with prolongation of late repolarisation and the 
ERP, in atrial isolated myocytes [22]. However, the influences of such treatment on atrial cellular 
electrophysiological responses to ET-1 are unknown. 
 The aim of this study, therefore, was two-fold. Firstly, to investigate effects of ET-1 and the 
sympathomimetic isoproterenol (ISO), alone and in combination, on human atrial cellular action potential 
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morphology, ERP, arrhythmogenic electrophysiological activity and ICaL. Secondly, to compare these effects 
between groups of patients treated and not treated chronically with a β-blocker. 
 
 
Materials and Methods. 
Right atrial appendage tissue (weight: 0.39±0.03 g) was obtained from 66 consenting patients in sinus 
rhythm undergoing cardiac surgery. Procedures were approved by the institutional research ethics 
committee. Atrial cells were isolated by enzymatic dissociation and mechanical disaggregation, using 
protease (Type XXIV, 4 U/ml, Sigma) and collagenase (Type 1, 330 U/ml, Worthington), as described 
previously [16,22]. 
 Action potentials and ICaL were recorded using the whole-cell patch clamp technique, in perforated-
patch configuration to limit intracellular dialysis. Glass microelectrodes were pulled and heat-polished to 
1.5-5 MΩ. Cells were superfused at 35-37
o
C, at 1.5-2 ml/min with a physiological salt solution, containing 
(mM): NaCl (130), KCl (4), CaCl2 (2), MgCl2 (1), glucose (10) and HEPES (10); pH 7.4. An Axopatch-1D 
amplifier (Axon Instruments) and “WinWCP” software (donated by J Dempster, Strathclyde University) 
were used to stimulate and record electrical activity. Signals were low-pass filtered at 5 kHz prior to 
digitisation (Digidata 1200, Axon). Following seal formation, the time course of series resistance (Rs) 
reduction due to perforation was bi-exponential, with mean fast and slow phase half lives of 93 and 297 s, 
respectively (n=165 cells), with stabilisation (typically after ~10 min) at 7.2±0.2 MΩ. Cells with Rs>20 MΩ 
were excluded. Mean cell capacity was 83±1 pF. Capacitative transients were subtracted electronically from 
the recordings. The voltage drop across Rs was routinely compensated electronically, by 68±0%, limiting 
maximum voltage errors to <3 mV. Action potentials were recorded using a K
+
 based intracellular solution, 
containing (mM): nystatin (0.18), K methanesulfonic acid (100), KCl (30), NaCl (5), MgCl2 (1), HEPES (5); 
pH 7.3. A liquid junction potential (+5 mV, bath relative to pipette) was compensated prior to sealing. Action 
potentials were stimulated with 5 ms current pulses of 1.2 x threshold, with an 8-pulse (S1) conditioning train 
at 75 beats/min. All cells were current-clamped (with hyperpolarising current of <150 pA) to a diastolic 
potential of -75 to -80 mV, with holding current kept constant in each cell thereafter. Action potential traces 
were scanned for the presence of “cellular arrhythmic depolarisations” (CADs), defined as any phase 3 
transient depolarisation or phase 4 depolarisation of >3 mV. Action potential restitution was investigated 
with progressively premature test pulses (S2) following the S1 trains, with S1 and S2 of equal magnitude. The 
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cells’ ERP was calculated as the longest S1-S2 interval failing to elicit an S2 response of amplitude >80% of 
that of the preceding S1 [16,22]. ICaL was recorded using a Cs
+
 based pipette solution to eliminate outward K
+
 
currents, containing (mM): nystatin (0.18), Cs methanesulphonic acid (100), CsCl (30), NaCl (5), MgCl2 (1), 
HEPES (5); pH 7.3. ICaL was measured from a holding potential of -40 mV, with 250 ms voltage pulses (0.33 
Hz), increasing from -30 to +60 mV in 10 mV steps. The time course of change in peak ICaL was examined 
using repetitive (0.2 Hz) 250 ms pulses from -40 to +10 mV. All drugs were prepared as stock solutions in 
H2O, stored frozen and protected from light. ET-1, ISO, and the ETB agonist sarafotoxin were obtained from 
Sigma. The ETA antagonist FR139317 was obtained from SNPE England. 
 Details of patients’ clinical characteristics and drug treatments were obtained from the case notes, and 
are shown in Table 1. Values are means±SE. ISO concentration-ICaL response data were fitted iteratively with 
a variable slope sigmoidal curve, using the Hill equation and Graphpad Prism software. Differences between 
means were assessed using paired or unpaired Student's t tests, as appropriate. The incidences of occurrence 
of CADs were compared using a χ
2
 test, with Yates’ Correction. P<0.05 was taken as statistically significant. 
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Results. 
 
Effects of isoproterenol, endothelin-1 and their combination, on human atrial L-type Ca
2+
 current. 
Isoproterenol (0.05 µM) produced a marked and significant increase in peak ICaL, from -5.5±0.4 to -14.6±0.9 
pA/pF (P<0.05, n=79 cells, 34 patients). Figure 1A, upper panel shows original ICaL recordings from a single 
atrial cell, representative of this response. The effect of ISO peaked within 2 min (Figure 1A, middle panel). 
Only cells displaying a stable response to ISO were used for subsequent investigation. The ICaL response to 
ISO was concentration-dependent (10
-10
-10
-6
 M), with Emax of 210±15% above control, and EC50 of 2.3x10
-8
 
M (n=4-79 cells, 3-34 patients). The co-application of ET-1 and ISO reversed the ISO-induced ICaL increase 
(Figure 1A, upper panel), returning ICaL to approximately basal amplitude (middle panel). This was 
confirmed by mean data from 11 patients (lower panel). The degree of this anti-adrenergic effect, expressed 
as the absolute ICaL reduction by ET-1 from the ISO value as a function of the absolute ICaL increase by ISO, 
was 98±10% with 10 nM ET-1 (n=14 cells, 11 patients). ET-1 at lower concentrations also produced marked 
and significant anti-adrenergic effects on ICaL: by 96±17% at 1 nM (n=4 cells, 2 patients), 91±22% at 0.1 nM 
(n=4 cells, 2 patients), and by 93±26% at 0.01 nM (n=4 cells, 4 patients). By contrast, ET-1 (10 nM) had no 
significant effect on basal ICaL, i.e. in the absence of adrenergic stimulation. This is demonstrated in Figure 
1B by original ICaL traces (upper panel), by the lack of change in ICaL during ET-1 application and washout 
(middle panel), and by the lack of a significant effect of ET-1 on mean basal ICaL (lower panel). 
 
Endothelin-receptor involvement in L-type Ca
2+
 current response to ET-1. 
The ETA antagonist FR139317 (10 nM) partially reversed the anti-adrenergic effect of 10 nM ET-1 on ICaL. 
Figure 2A shows that FR139317 produced a gradual increase in ICaL after the characteristic ET-1 response, in 
the continued presence of ISO and ET-1. FR139317 exerted a similar effect in each of 6 cells (4 patients), 
with a significant reversal of the anti-adrenergic effect of ET-1 by 22±7% (P<0.05). Figure 2B shows that 
FR139317 had no effect on ISO-stimulated ICaL, and when co-applied prior to ET-1, prevented the anti-
adrenergic effect of ET-1. The ETB agonist sarafotoxin (S6c) at 10 nM had no effect on basal (non-ISO-
stimulated) ICaL (Figure 2C). ICaL in the absence and presence of S6c was -3.9±1.1 and -3.3±0.8 pA/pF, 
respectively (P>0.05, n=5 cells, 3 patients). Following S6c washout, ISO stimulated an increase in ICaL which 
was unaffected by the re-addition of S6c, but which was reversed by ET-1 in the continued presence of S6c 
(Figure 2C). 
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Effects of ISO and ET-1 on action potentials and effective refractory period. 
Isoproterenol at 0.05 µM elevated the action potential plateau, as shown by the original recordings in Figure 
3A (upper panel). This was associated with a marked prolongation of early and mid repolarisation, but later 
repolarisation was unaffected (Figure 3A, upper panel). The action potential duration at 50% repolarisation 
(APD50) was 54±10 ms in the presence of ISO, significantly longer (by 93%) than in its absence, at 28±5 ms 
(P<0.05), but neither the APD75 (163±21 vs 154±13 ms, P>0.05) nor APD90 (204±16 vs 220±14 ms; P>0.05; 
n=22 cells, 12 patients) were significantly affected. Endothelin-1 (10 nM) fully reversed the effect of 0.05 
µM ISO on the action potential, returning its morphology approximately to the pre-ISO state. This is shown 
in Figure 3A, upper panel, with confirmatory mean data from 10 patients given in the lower panel. Figure 3B 
(upper panel) shows that 0.05 µM ISO had no effect on either action potential restitution or the cellular ERP, 
in line with its lack of effect on APD90. These measurements also were unaffected by the combination of 
0.05 µM ISO and 10 nM ET-1. The absence of changes in ERP were confirmed by mean data in Figure 3B 
(lower panel). Figure 4A shows that ET-1 (10 nM) had no significant effect on action potential shape or 
mean APD50 in the absence of ISO. Endothelin-1 (10 nM) also had no significant effect, in the absence of 
ISO, on APD75 (132±13 ms in control vs 142±13 ms with ET-1), APD90 (210±17 vs 226±20 ms; n=21 cells, 
5 patients), nor action potential maximum upstroke velocity, Vmax (198±23 vs 183±20 V/s; n=9 cells, 5 
patients; P>0.05 for each). Furthermore, ET-1 also had no significant effect on basal action potential 
restitution or the cellular ERP (Figure 4B). 
 
Cellular arrhythmic depolarisations induced by ISO, and anti-adrenergic effect of ET-1. 
Action potentials recorded using a repetitive stimulation protocol in the presence of ISO (0.05 µM) were 
frequently interrupted by low amplitude, usually sub-threshold, transient depolarisations. We have termed 
these “cellular arrhythmic depolarisations” (CADs). Figure 5Ai shows original recordings of phase 4 CADs 
produced by ISO. The control APD50 was 24 ms, and this was increased by ISO to 51 ms. Endothelin-1 (10 
nM) abolished these ISO-induced CADs, associated with reversal of the plateau elevation (APD50: 32 ms). 
Figure 5Aii shows action potentials with a control APD50 of above average value (67 ms at steady-state). In 
this cell, ISO produced relatively large amplitude CADs, associated with a relatively large increase in APD50 
compared with that of Figure 5Ai. Many, but not all of these CADs occurred during phase 3: a single CAD 
reached threshold just prior to the 6th driven beat (Figure 5Aii). Each of these CADs was abolished by ET-1 
(Figure 5Aii), again with an associated anti-adrenergic effect on early repolarisation. Figure 5Aiii shows the 
  8/25
typical response to ET-1 in the absence of ISO, i.e. lack of production of CADs. Figure 5B shows that ISO 
produced CADs in a significant number of cells (panel i) and that, in cells in which ISO and ET-1 were co-
applied, ET-1 abolished ISO-induced CADs (panel ii). By contrast, ET-1 alone had no significant effect on 
the incidence of CADs (panel iii).  
 
Effects of β-blocker therapy on basal electrophysiology and responses to ISO and ET-1. 
The atrial cell basal ERP, i.e. in the absence of ISO, was significantly longer in a group of patients treated 
with a β-blocker for ≥7 days pre-operatively (221±9 ms; 50 cells, 13 patients), than in a group of non-β-
blocked patients (184±15 ms; 22 cells, 7 patients; P<0.05). However, there were no significant differences 
between these patient groups in the basal electrophysiological measurements which were shown 
subsequently to be affected by either ISO or ET-1. The basal peak ICaL density and the basal ICaL voltage-
dependency were similar in the two patient groups (Figure 6, panels A and B). The basal APD50 also was not 
significantly affected (panel C). Furthermore, the magnitude of neither of the observed significant effects of 
0.05 µM ISO, i.e. to increase peak ICaL and APD50, was significantly different between these patient groups 
(panels D and E, respectively). Finally, there was no significant difference between β-blocked and non-β-
blocked patient groups in the subsequent ET-1 (10 nM)-induced reduction in APD50 (panel F).  
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Discussion. 
The effects of ET-1 on action potentials were studied for the first time to our knowledge in human atrium. 
Endothelin-1 exerted a marked anti-adrenergic action, abolishing the prolongation of APD produced by ISO. 
By contrast, ET-1 had no significant basal action, i.e. in the absence of adrenergic stimulation. The effects of 
ET-1 on action potentials have been studied only rarely in the atrium of any species [23-25]. Anti-adrenergic 
effects have not been investigated and the basal responses are equivocal [23-25]. Endothelin-1 raised the 
plateau of “slow response action potentials” in guinea-pig atrium [23]. It also shortened the APD in guinea-
pig [24] and canine [25] atria. In the ventricle, by contrast, numerous studies, particularly canine have 
demonstrated an APD prolonging action of ET-1 [4-6,26]. 
 In the present study, ET-1 abolished atrial cellular arrhythmic depolarisations (CADs) provoked by ISO 
during action potential trains. We studied single cells, so this can be considered to be a direct 
electrophysiological effect of ET-1, not secondary to, for example, coronary vasoconstriction. Endothelin-1 
did not produce significant numbers of CADs in the absence of adrenergic stimulation, even at a 10
3
-fold 
higher concentration than was anti-adrenergic on ICaL. By contrast, ET-1 induced arrhythmic contractions in 
human atrial tissues [9,11]. Atrial contraction was not measured in the present study, and ET-1 exerts various 
contractile effects not requiring electrophysiological changes [1,2]. These may include enhanced Ca
2+
-
induced Ca
2+
 release (CICR) by IP3 activation, phosphorylation of myosin light chains, and enhancement of 
myofilament Ca
2+
 responsiveness. Some may account, at least in part, for the apparent discrepancy between 
the effect of ET-1 to induce arrhythmic contractions but not to produce CADs. Methodological differences 
between studies may contribute also, e.g. with blockade of β1 and β2 adrenoceptors in both contraction 
studies [9,11]. Furthermore, arrhythmic contractions induced by ET-1 are not mediated by ETA receptors 
[11]. Since effects of ET-1 on ICaL were mediated by ETA, in the present and other studies [13,14], the 
arrhythmic contractions may be largely independent of ICaL. In support, effects of ET-1 on atrial contractility 
were shown to not require an involvement of ICaL, even though its involvement could also be demonstrated 
[27]. Endothelin-1 elevated (Ca
2+
)i concentration, Ca
2+
 transient amplitude and spark frequency in rat, cat 
and mouse atria, via IP3 activation [7,8,10]. It also induced diastolic premature Ca
2+
 transients [7] and 
facilitated arrhythmogenic Ca
2+
 waves [8]. In one of these studies [7], premature Ca
2+
 transients were 
accompanied by action potentials. These effects of ET-1 on (Ca
2+
)i could exert an arrhythmogenic influence 
in the atria of patients. Such extrapolation should be made with caution, however. The atrial studies [7,8,10] 
were not on human tissues, and the lowest concentration of ET-1 used in each (100 nM) was ~10
4
-fold 
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greater than the highest levels reported in patients (6-12 pM) [20,28]. In the studies showing pro-arrhythmic 
effects of ET-1 on contractility [9,11] and (Ca
2+
)i handling [7,8,10], the atrial tissues were not under 
adrenergic stimulation. However, ET-1 produced marked negative inotropism in human atrium in the 
presence of catecholamines [29]. Therefore, ET-1 exerts marked anti-adrenergic effects on atrial 
contractility, as well as on CADs. 
 The CADs produced by catecholamine in this study occurred in cells with a relatively marked 
prolongation of the APD. This is consistent with the reported association between APD lengthening and the 
development of afterdepolarisations [17]. Many of these CADs displayed characteristics of abnormal 
automaticity, and possibly EADs or DADs. Their suppression by ET-1 could, therefore, contribute an 
inhibitory influence on non re-entrant mechanisms of AF. Consistent with that, intracoronary ET-1 prevented 
AF produced by intravenous ISO in dogs [5]. Furthermore, ET-1 lacked effect on either the cellular ERP or 
the action potential Vmax. This suggests that ET-1 may not alter the minimum path length for re-entry, and 
therefore not promote (or inhibit) re-entrant AF. The anti-adrenergic effects of ET-1 were observed at 
extremely low, clinically relevant concentrations (down to 10 pM), despite near-maximal adrenergic 
stimulation. They might be expected to occur also, therefore, in patients with CHF whose catecholamine 
levels are elevated [20]. Nevertheless, extrapolation should be made with caution, since it is presently 
unknown whether such effects of ET-1 would be preserved in patients with AF or CHF. Of note, the 
modulation of ICaL by PKC, which is involved in ET-1 signalling [30,31], was impaired in chronic AF [32]. It 
is also unclear whether AF causes ET-1 elevation in the absence of CHF or other myocardial diseases [33]. 
Furthermore, the chronic effects of ET-1, rather than the relatively acute effects studied here and elsewhere, 
are presently unknown. These could include, for example, a long term adaptive response akin to 
“pharmacological remodelling” [22]. 
 Afterdepolarisations are affected by changes in ICaL [17]. In the present study, this current was reduced 
markedly by ET-1 when adrenergically stimulated, whilst non-adrenergically stimulated ICaL was unaffected. 
We limited cytosolic dialysis, and thus efflux of intracellular messengers required for ET-1 signalling, by 
using the perforated patch configuration. In a study using ruptured patch, ET-1 reduced basal ICaL in human 
atrium [13]. However, in line with the present data, it had no effect on basal ICaL when intracellular GTP was 
present [13]. In another study, ET-1 either increased or decreased human atrial basal ICaL, depending on the 
pre-ET-1 ICaL density, again using ruptured patch [14]. In the atria of other species, either an absence of 
effect of ET-1 on basal ICaL [12,34] or a decrease [24] have been demonstrated. However, no reports of ICaL 
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increase by ET-1 were found in atrium. The effects of ET-1 on basal ICaL in the ventricles have been studied 
more widely. These include a decrease [26,35], no change [15,36] or an increase [37,38]. In each of these 
atrial and ventricular studies in which basal and anti-adrenergic effects of ET-1 were compared [12-
15,34,36,37], the most consistent and predominant effect was an anti-adrenergic reduction in ICaL. This has 
been shown to involve cAMP and Gi protein in human atrial cells [14]. The present conformity of effects of 
ISO, ET-1 and their combination on ICaL, APD and CADs suggests that CAD abolition by ET-1 involved the 
anti-adrenergic reduction in ICaL. Consistent with this, an ICaL agonist produced APD lengthening and EADs 
in canine myocardial bundle branch, and each effect was abolished by an ICaL blocker [4]. The reduction in 
ICaL by ET-1 also may involve (Ca
2+
)i-induced inactivation of this current, via enhanced CICR [9,10]. 
Furthermore, a Cl
-
 current activated by ISO and cAMP was inhibited by ET-1 in human atrial cells [39]. 
However, this current was present in ~20% of cells and required 30 nM ET-1 to affect. Endothelin-1 
increased the human atrial Na
+
 current (INa) [13]. This was measured using low extracellular Na
+
 
concentration ([Na
+
]o) at 22
o
C. However, we and others [6,26] found no significant effect of ET-1 on action 
potential Vmax, a reliable indicator of INa, at physiological [Na
+
]o and temperature. Nevertheless, effects of 
ET-1, either basal or anti-adrenergic, on currents additional to ICaL cannot be excluded. 
 Chronic treatment of patients with a β-blocker was associated with a prolonged atrial cellular ERP, in 
the absence of adrenergic stimulation. This is considered to be a component of “pharmacological 
remodelling”, since the β-blocker is presumed to be removed by the repeated washing of cells during their 
isolation [22]. The basal APD50 and ICaL were unchanged by chronic β-blockade, also consistent with the 
earlier study [22]. In the present study, chronic β-blockade did not influence the effects of ISO or the anti-
adrenergic effects of ET-1 on these measurements. Such patient treatment has been associated with 
potentiation of atrial arrhythmic contractions by β2-adrenoceptor stimulation [21] and by ET-1 [11], though 
anti-adrenergic actions of ET-1 were not investigated [11]. The present data are in line with a reported lack 
of influence of chronic β-blockade on human atrial ICaL responses to ET-1 [14]. The concentrations of ISO 
and ET-1 we used indicate that the Emax of the electrophysiological responses was unaffected by chronic β-
blockade. However, the possibility that the potency of these responses may be affected, cannot be excluded. 
 The present data suggest that ET-1 may contribute a potentially anti-arrhythmic electrophysiological 
influence in human atrium in the presence of adrenergic stimulation. This influence may not be affected by 
the treatment of patients with β-blockers. It should be considered alongside the potentially pro-arrhythmic 
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influences of ET-1 on (Ca
2+
)i handling and myocardial contractility in the absence of adrenergic stimulation. 
Elevation of ET-1 is an adverse prognostic marker in CHF [40]. However, ET-receptor antagonists do not 
reduce mortality, despite their short term haemodynamic benefit, in patients with CHF [41]. It is conceivable 
that potentially beneficial electrophysiological influences of ET-1 might be blunted by the blockade of 
cardiac ET-receptors.  
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Table and Figure legends. 
Table 1. Patients’ characteristics. 
Values are numbers of patients (n, % of total) with selected clinical characteristics, except for age 
(mean±SE). CCB=calcium channel blocker, CABG=coronary artery bypass graft surgery, AVR=aortic valve 
replacement, LVD=left ventricular dysfunction, MI=myocardial infarction. 
Figure 1. 
Anti-adrenergic effect of endothelin-1 on human atrial L-type Ca
2+
 current. 
Comparison of effect of 10 nM ET-1 (striped symbols) on peak ICaL (at +10 mV) in the presence, A, and 
absence, B, of 0.05 µM ISO (filled symbols), relative to basal (non-ISO-stimulated) ICaL (open symbols). 
Upper panels: original, superimposed ICaL recordings, with chronological order labelled, from single atrial 
cells. Dotted lines=zero pA. Calibration applies to both panels. Middle panels: time course of change in ICaL 
by drugs, represented by horizontal bars (n=1 cell/panel). Lower panels: histograms of mean±SE ICaL. Data 
are paired: 14 cells, 11 patients in A; 5 cells, 3 patients in B. Asterisks=P<0.05; NS=not significant. 
Figure 2. 
Effects of ET-receptor antagonist and agonist on ICaL response to ET-1. 
Time course of change in peak ICaL by application (horizontal bars) of an ETA antagonist, FR139317, 10 nM 
(FR, 
 
), an ETB agonist, sarafotoxin, 10 nM (S6c, 
 
), 10 nM ET-1 (
 
) and/or 0.05 µM ISO (
 
). n=1 
cell/panel. A, Partial reversal by FR139317 of anti-adrenergic effect of ET-1 on ICaL. B, Prevention by 
FR139317 of the ET-1 anti-adrenergic effect, and lack of effect of FR139317 on ISO-induced ICaL increase. 
C, Lack of effect of S6c on basal or ISO-stimulated ICaL, or on anti-adrenergic action of ET-1.  
Figure 3. 
Effects of ISO and ET-1 on action potentials and effective refractory period. 
A, Action potential waveform and duration at 50% repolarisation (APD50) and B, Restitution and effective 
refractory period (ERP) in atrial cells, in the absence of a drug (
 
), following 0.05 µM ISO (
 
) and 
subsequent co-application of 10 nM ET-1 (
 
). Upper panels: original, superimposed action potentials, from 
the same cell, produced by (A) the 7th of a train of conditioning current pulses (75 beats/min) and (B) the 7th 
and 8th conditioning pulses followed by progressively premature test pulses. Horizontal bars=cell ERP. 
Lower panels: histogram data; paired means (n=15 cells, 10 patients). 
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Figure 4. 
Lack of effect of ET-1 on basal action potential repolarisation and ERP. 
A, Action potential waveform and mean APD50, and B, Restitution and mean ERP, in absence of a drug (
 
) 
and following 10 nM ET-1 (
 
). Upper panels: superimposed responses to (A) 7th conditioning pulse and 
(B) in a different cell, to the 7th and 8th conditioning pulses followed by premature test pulses. Horizontal 
bars=ERP. Lower panels: paired means of APD50 (21 cells, 5 patients) and ERP (16 cells, 5 patients). 
Figure 5. 
Cellular arrhythmic depolarisations induced by ISO, and abolished by ET-1. 
A, Original action potentials (APs) evoked by trains of current pulses (75 beats/min) in the absence of a drug 
(
 
), with 0.05 µM ISO (
 
) and subsequent 10 nM ET-1 (
 
) in (i) a cell with a normal AP plateau, and (ii) 
a cell with relatively high plateau. Arrows indicate “cellular arrhythmic depolarisations” (CADs): any AP 
phase 3 transient depolarisation or phase 4 depolarisation >3 mV. Dots indicate driven beats. iii, typical 
absence of response to ET-1 without ISO. All initial APs are post-rest. B, Histograms showing (i) significant 
production of CADs by ISO (
 
), (ii) abolition of CADs by ET-1, (iii) lack of significant (NS) CAD 
production by ET-1 (
 
). Numbers within columns=n cells displaying CADs/total studied.  
Figure 6. 
Lack of effect of chronic β-blocker therapy on atrial electrophysiological responses to ISO and ET-1.  
Comparison of L-type Ca
2+
 current (ICaL), action potential duration at 50% repolarisation (APD50) and their 
responses to isoproterenol at 0.05 µM (ISO) and endothelin-1 at 10 nM (ET-1), between patients treated ≥7 
days with a β-blocker (
 
& ; “+BB”) and those not treated with a β-blocker (
 
&
 
; “-BB”). A, Basal (i.e. 
in absence of a drug) peak ICaL. B, Basal ICaL voltage-dependency, with ICaL expressed at each voltage as a 
function of peak current. C, Basal APD50. D, Absolute increase in ICaL produced by ISO. E, Absolute increase 
in APD50 produced by ISO. F, Absolute reduction in APD50 produced by ET-1 in the presence of ISO. 
Values are means±SE. NS=not significant. Group sizes (c=cells, p=patients): A, +BB: 114c, 34p, -BB: 52c, 
13p; B, +BB: 62c, 21p, -BB: 22c, 7p; C, +BB: 55c, 13p, -BB: 23c, 7p; D, +BB: 61c, 25p, -BB: 18c, 9p; E, 
+BB, -BB: 11c, 6p each; F, +BB: 7c, 5p, -BB: 8c, 5p. 
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Table 1. 
  n % 
Patient details Male/female 52/14 79/21 
 Age (years) 64±1 - 
Drug treatments Lipid lowering 57 86 
 β-blocker 48 73 
 Nitrate 40 61 
 ACE inhibitor 32 48 
 CCB 21 32 
 Diuretic 20 30 
Operation type CABG 59 89 
 AVR 6 9 
 CABG+AVR 1 2 
LV function Normal 33 50 
 Mild/moderate LVD 28 42 
 Severe LVD 4 6 
Disease Angina 61 92 
 Hyperlipidaemia 53 80 
 Hypertension 38 58 
 Previous MI 33 50 
 Diabetes 7 11 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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